Continued exploration of the mechanisms underlying PI3K pathway dysregulation will aid in developing targeted therapies, potentially improving outcomes for patients with gastrointestinal tumors (Michl and Downward, 2005; Zhang et al., 2011; Su et al., 2022). The gene discussed is PIK3CD; the disease is digestive system neoplasm.